Skip to content
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
Subscribe

Evommune’s EVO756 Performs Well in Phase 2 Study of Adults With CIndU

Fully 30% of adult chronic inducible urticaria (CIndU) patients achieved a complete response after four weeks of dosing with EVO756, a potent, highly selective oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2).

The Dermatology Digest is an independent, multi-channel resource for practicing dermatologists and dermatological practitioners.

Quick Links
  • Advertise with Us
  • About Us
  • Advertise with Us
  • About Us
Follow us
Linkedin Facebook-f X-twitter Youtube

© 2026 All Rights Reserved.